Looking for a Clinical Trial?
A cancer clinical trial is a carefully controlled research study conducted by
doctors to improve the care and treatment of cancer patients. The purpose of clinical trials to treat leukemia, lymphoma, myeloma, myelodysplastic syndromes or other blood cancers is
To improve treatment options, increase survival and
Improve quality of life.
To find out if you are eligible for a clinical trial, go to the TrialCheck® Web site, a clinical trial search service that offers patients and caregivers immediate access to listings of all lymphoma clinical trials. Answer just a few simple questions and a list of available clinical trials related to your cancer will appear in an easy to read list of search results.
You may also want to visit the National Cancer Institute's Cancer Trials Support Unit, providing resources and information on phase III cancer treatment trials supported by the National Cancer Institute.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
